Previous 10 | Next 10 |
home / stock / vrtx / vrtx articles
U.S. stocks are attempting to post the longest streak of consecutive positive sessions in over two years. As of midday trading in New York, both th...
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported upbeat earnings for its third quarter, while sales missed estimates. Vertex Pharmaceuti...
Sentiment appears to have dipped after a six-session winning streak. Stock futures indicate a modestly lower opening on Tuesday as small and mid-ca...
The market looks set to extend last week’s gains, with the stock futures holding up early Monday ahead of a slew of earnings reports mostly f...
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 9.66% on an annualized basis producing an average annual...
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet next week, Tuesday, 31 October, to discuss whether V...
In the current market session, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) stock price is at $361.86, after a 0.81% decrease. However, over the past ...
The Nasdaq 100 closed lower by over 200 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell share...
Cantor Fitzgerald has downgraded CRISPR Therapeutics AG (NASDAQ: CRSP) to Neutral from Overweight, noting that its sickle cell ...
News, Short Squeeze, Breakout and More Instantly...
Vertex Pharmaceuticals Incorporated Company Name:
VRTX Stock Symbol:
NASDAQ Market:
Vertex Pharmaceuticals Incorporated Website:
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations Canada NewsWire -Approximately 200 people with certain rare CF mutations are now ...